GLP-1 Receptor Agonists: Clinical Pearls for Patient Success

Claim your seat today!

Join us for an engaging continuing education activity focused on the evolving role of GLP-1 and GIP receptor agonists in obesity management. Explore the science behind these therapies and their impact on appetite regulation, weight management, insulin sensitivity, and overall metabolic health.

Participants will review current evidence, clinical applications, patient selection criteria, contraindications, adverse effect management, and emerging therapies in obesity medicine. The program will also address long-term treatment strategies, preservation of lean muscle mass, and the unique challenges of weight management during perimenopause and menopause.

Designed for nurses and other healthcare professionals, this session will provide practical, evidence-based insights to support individualized, patient-centered obesity care. Upon completion, learners will be able to identify at least one evidence-based strategy for optimizing the safe and effective use of GLP-1/GIP receptor agonists in clinical practice.

Target Audience

Registered nurses and other interested healthcare professionals

Objectives

At the conclusion of the educational activity, participants will be able to:

1. Explain the physiology of GLP-1 and GIP hormones.
2. Describe the mechanism of action of GLP-1/GIP receptor agonists.
3. Apply current evidence and clinical guidelines when selecting patients for therapy.
4. Recognize contraindications, adverse effects, and monitoring strategies.
5. Incorporate obesity medicine principles into individualized treatment plans.

Participants can earn 1.5 contact hours of nursing continuing professional development credit. Each nursing participant must be present for the entire session and complete a session evaluation to receive credit.

Presenter

Alison L. Thornhill DNP, APRN, FNP-C

Location

Accessible via Zoom.

Disclosures

No relevant financial relationships were identified for any individual who can control this activity’s content. The presenter and activity planners for this educational activity have disclosed no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.